{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:07:03Z","timestamp":1790140023577,"version":"4.0.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tacrolimus dosing during the immediate postoperative period after pediatric liver transplantation is challenging because clearance can change rapidly as graft function recovers, while conventional weight-based dosing provides limited guidance for incorporating measured concentrations into subsequent doses. We developed a population pharmacokinetic model of tacrolimus in recipients younger than 36 months and evaluated its application to model-informed precision dosing (MIPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Routine therapeutic drug monitoring data collected through postoperative day 11 were analyzed using nonlinear mixed-effects modeling. Sampling occasions were stratified into six predefined postoperative intervals, and inter-occasion variability in apparent clearance was estimated separately for each occasion. Model performance was evaluated using goodness-of-fit diagnostics, an occasion-stratified prediction-corrected visual predictive check, and Monte Carlo simulation of individual concentration\u2013time profiles. MIPD was implemented using two complementary approaches: a covariate-based equation for initial dosing and maximum a posteriori Bayesian forecasting for subsequent dose refinement. Forward predictive performance was also evaluated by forecasting the trough concentration at the next occasion using covariates alone or in combination with one or two preceding trough measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 731 tacrolimus concentrations from 92 patients were analyzed. A one-compartment model with first-order absorption adequately described the data. Clearance decreased with increasing total bilirubin and aspartate aminotransferase, whereas volume of distribution increased with age. Inter-occasion variability in clearance varied across the postoperative course, from a coefficient of variation of 123.8% on postoperative day (POD) 2%\u201310.7% on POD 5\u20136, before increasing to 38.8% on POD 9\u201311. Monte Carlo simulation placed 89.2% of observed concentrations within the 90% prediction interval. Moreover, incorporating one preceding trough reduced the mean absolute error of next-occasion predictions by approximately one-fifth, while incorporating two preceding troughs reduced it by approximately one-third, according to the performance validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Tacrolimus clearance in pediatric liver transplant recipients younger than 36 months is characterized by substantial occasion-specific variability during the immediate postoperative period, consistent with dynamic changes in graft function. Dose individualization should therefore incorporate occasion-specific therapeutic drug monitoring data. The developed model provides a quantitative framework for MIPD, implemented here through a publicly accessible web application (\n                      <jats:ext-link>https:\/\/smjlab.shinyapps.io\/fk506_frontiers\/<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1896778","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:48:47Z","timestamp":1790138927000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Population pharmacokinetic modeling of tacrolimus using real-world data for precision dosing in pediatric liver transplant recipients younger than 36 months during the immediate postoperative period"],"prefix":"10.3389","volume":"17","author":[{"given":"Soo-Min","family":"Jung","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]},{"name":"Department of Pediatric Surgery, Asan Medical Center Children\u2019s Hospital, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyu","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Hyang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungchan","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyun-Seop","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong-Seok","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine","place":["Seoul, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/01.sla.0000189131.90876.9e","article-title":"The \u201c50-50 criteria\u201d on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy","volume":"242","author":"Balzan","year":"2005","journal-title":"Ann. Surgery"},{"key":"B3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/pharmaceutics17050619","article-title":"Pharmacokinetics of different tacrolimus formulations in the early post-liver transplant period: a scoping review","volume":"17","author":"Barriga-Rodr\u00edguez","year":"2025","journal-title":"Pharmaceutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif. Organs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS Journal"},{"key":"B6","doi-asserted-by":"publisher","first-page":"750672","DOI":"10.3389\/fphar.2021.750672","article-title":"Population pharmacokinetic model development of tacrolimus in pediatric and young adult patients undergoing hematopoietic cell transplantation","volume":"12","author":"Brooks","year":"2021","journal-title":"Front. Pharmacology"},{"key":"B7","article-title":"Population pharmacokinetics of tacrolimus in liver transplant patients","author":"Bruce","year":"1995"},{"key":"B8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monitoring"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1031969","DOI":"10.3389\/fphar.2022.1031969","article-title":"Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: a comparison of michaelis-menten and theory-based pharmacokinetic models","volume":"13","author":"Cai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1632588","DOI":"10.3389\/fphar.2025.1632588","article-title":"Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation","volume":"16","author":"Cao","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/pan.14710","article-title":"Intraoperative fluid administration volumes during pediatric liver transplantation and postoperative outcomes: a multicenter analysis","volume":"33","author":"Efune","year":"2023","journal-title":"Pediatr. Anesth."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00228-013-1501-0","article-title":"Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation","volume":"69","author":"Guy-Viterbo","year":"2013","journal-title":"Eur. Journal Clinical Pharmacology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/bcp.14434","article-title":"TDM is dead. Long live TCI","volume":"88","author":"Holford","year":"2022","journal-title":"Br. Journal Clinical Pharmacology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jamcollsurg.2013.01.004","article-title":"A risk model to predict 90-day mortality among patients undergoing hepatic resection","volume":"216","author":"Hyder","year":"2013","journal-title":"J. Am. Coll. Surg."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","article-title":"Population Pharmacokinetic Models of Tacrolimus in Adult Transplant Recipients: a Systematic Review: R. Kirubakaran et al","volume":"59","author":"Kirubakaran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1592\/phco.26.8.1069","article-title":"Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients","volume":"26","author":"Lee","year":"2006","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/00007890-199609150-00029","article-title":"Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure","volume":"62","author":"Lo","year":"1996","journal-title":"Transplantation"},{"key":"B18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","article-title":"Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients","volume":"72","author":"Moes","year":"2016","journal-title":"Eur. Journal Clinical Pharmacology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/FTD.0b013e31829dcbcd","article-title":"Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation","volume":"36","author":"Musuamba","year":"2014","journal-title":"Ther. Drug Monitoring"},{"key":"B20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/lt.23966","article-title":"Liver regeneration after living donor transplantation: adult\u2010to\u2010adult living donor liver transplantation cohort study","volume":"21","author":"Olthoff","year":"2015","journal-title":"Liver Transplant."},{"key":"B21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1046\/j.1365-2125.2000.00288.x","article-title":"Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients","volume":"50","author":"Sam","year":"2000","journal-title":"Br. Journal Clinical Pharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3748\/wjg.15.648","article-title":"Pediatric liver transplantation","volume":"15","author":"Spada","year":"2009","journal-title":"World Journal Gastroenterology WJG"},{"key":"B23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin. Pharmacokinetics"},{"key":"B24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin. Pharmacokinetics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.3892\/etm.2019.7446","article-title":"Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models","volume":"17","author":"Wang","year":"2019","journal-title":"Exp. Ther. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1896778\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:48:58Z","timestamp":1790138938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1896778\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1896778"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1896778","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1896778"}}